Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SenesTechSNES -1.96%34 3-Year EBITDA Growth Rate is 88.80% as of Jun. 2026, which is 13% above its 10-year median of 78.90. GuruFocus rates SNES with a GF Score™ of 34/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,411 Chemicals companies, SenesTech ranks better than 98.02% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 88.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 81.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of SenesTech was 88.80% per year. The lowest was 47.80% per year. And the median was 78.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
SenesTech 3-Year EBITDA Growth Rate Related Terms
SNES vs CNEY, GLGI, BGLC: 3-Year EBITDA Growth Rate Comparison
For the Specialty Chemicals subindustry, SenesTech's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SenesTech 3-Year EBITDA Growth Rate vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, SenesTech's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where SenesTech's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 88.80% mean?
SenesTech (SNES) has a 3-Year EBITDA Growth Rate of 88.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SenesTech and its competitors. This is 13% above median its historical median of 78.90. Over the past decade, SenesTech's 3-Year EBITDA Growth Rate has ranged from 47.80 to 88.80. According to the industry distribution chart, SenesTech ranks #28 out of 1411 companies in the Chemicals industry, placing it in the top 2%.
Is SenesTech's 3-Year EBITDA Growth Rate too high?
SenesTech's current 3-Year EBITDA Growth Rate of 88.80% is 13% above median its 10-year median of 78.90. Over the past 10 years, this metric has ranged from a low of 47.80 to a high of 88.80. The Chemicals industry median 3-Year EBITDA Growth Rate is 0.70. SenesTech's value of 88.80% is 12585.7% above this industry median. Based on the distribution chart, SenesTech ranks #28 out of 1411 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, SenesTech has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SenesTech's 3-Year EBITDA Growth Rate compare to CNEY and GLGI?
According to the Chemicals industry distribution chart, SenesTech ranks #28 out of 1411 companies for 3-Year EBITDA Growth Rate. This places SenesTech in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 0.70. SenesTech's value of 88.80% is 12585.7% above this benchmark. Historically, SenesTech's own 3-Year EBITDA Growth Rate has ranged from 47.80 to 88.80 over the past decade. While the company's 10-year median is 78.90 vs. the industry median of 0.70, SenesTech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Chemicals company?
The median 3-Year EBITDA Growth Rate among Chemicals companies is 0.70, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SenesTech's current 3-Year EBITDA Growth Rate of 88.80% is 12585.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for SenesTech and its competitors. For the Chemicals industry, the median 3-Year EBITDA Growth Rate is 0.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SenesTech's current 3-Year EBITDA Growth Rate is 88.80%, which is 13% above median its own 10-year median of 78.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SenesTech stock overvalued right now?
Based on GuruFocus' analysis, SenesTech (SNES) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $1.01 — trading 129.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 88.80%, which is 13% above median its 10-year median of 78.90 and 12585.7% above the Chemicals industry median of 0.70. SenesTech's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For SenesTech (SNES), the current 3-Year EBITDA Growth Rate is 88.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SenesTech (SNES) Overvalued in 2026?
Based on GuruFocus' analysis, SenesTech stock appears to be overvalued.
The current stock price of $1.01 is trading 129.5% above its estimated GF Value™ of $0.44.
GuruFocus considers SenesTech to be Significantly Overvalued.
Key valuation signals for SNES:
3-Year EBITDA Growth Rate: 88.80% (13% above median its 10-year median of 78.90)
GF Value™: $0.44 vs. price of $1.01 (129.5% above fair value)
Industry Position: 12585.7% above the Chemicals median (#28 of 1411)
No single metric tells the full story. See the SNES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company has developed and are commercializing products for managing animal pest populations through fertility control and population management strategies. Its current products focus on rat and mouse populations, and are known as: ContraPest, Evolve Rat, and Evolve Mouse.
34GF Score
Get the complete analysis for SNES
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNES has been successfully added to your 
